Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

579
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
579
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

958
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
958
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

614
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
614
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

2.5K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
2.5K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

1.8K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.8K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding vamorolone treatment access for Canadians with Duchenne muscular dystrophy.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

A class of deep intronic <i>IGHMBP2</i> variants activate a shared cryptic splice donor, enabling correction of select variants with a single antisense oligonucleotide.

medRxiv : the preprint server for health sciences·2026
Same author

Efficacy and safety of risdiplam in patients with type 1 spinal muscular atrophy: a 3-year open-label extension of the two-part, phase 2 FIREFISH trial.

The Lancet. Child & adolescent health·2026
Same author

Supporting Self-Regulated Learning in Medical School: A National Survey.

Cureus·2026
Same author

Implementation of a neuromuscular clinical trial network: a rare disease model for enhancing clinical trial readiness, capacity, and access in Canada.

Orphanet journal of rare diseases·2026
Same author

Multifrequency Electrical Impedance Myography Enhanced with Machine Learning for Screening Patients with Neuromuscular Disorders.

Annals of biomedical engineering·2026

Related Experiment Video

Updated: Mar 3, 2026

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.5K

Developing standardized corticosteroid treatment for Duchenne muscular dystrophy.

Michela Guglieri1, Kate Bushby1, Michael P McDermott2

  • 1John Walton Muscular Dystrophy Research Centre, Newcastle University, United Kingdom.

Contemporary Clinical Trials
|April 29, 2017
PubMed
Summary

This clinical trial compares three corticosteroid regimens for Duchenne muscular dystrophy (DMD), aiming to standardize treatment and improve outcomes for boys with this condition.

Keywords:
DeflazacortDuchenne muscular dystrophyPrednisoloneRandomizedStandards of care

More Related Videos

Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

34.0K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.9K

Related Experiment Videos

Last Updated: Mar 3, 2026

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.5K
Assessing Functional Performance in the Mdx Mouse Model
10:32

Assessing Functional Performance in the Mdx Mouse Model

Published on: March 27, 2014

34.0K
Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy
09:18

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

10.9K

Area of Science:

  • Neurology
  • Pediatrics
  • Pharmacology

Background:

  • Corticosteroids are the only proven treatment to improve strength and function in Duchenne muscular dystrophy (DMD).
  • Corticosteroid prescription for DMD is inconsistent globally, with some regions not utilizing this vital treatment.
  • Standardizing corticosteroid treatment is crucial for optimizing care and developing new therapies for DMD.

Purpose of the Study:

  • To compare the effectiveness and safety of three frequently prescribed corticosteroid regimens in boys with DMD.
  • To standardize the management of DMD complications and the prevention of corticosteroid side effects.
  • To establish an optimal, standardized corticosteroid regimen for Duchenne muscular dystrophy.

Main Methods:

  • A multi-center, international clinical trial involving 300 boys aged 4-7 with DMD.
  • Random assignment to daily prednisone, daily deflazacort, or intermittent prednisone (10 days on/10 days off).
  • Minimum 3-year follow-up assessing a primary outcome of time to rise, forced vital capacity, and patient/parent satisfaction.

Main Results:

  • The study is ongoing, results are pending.
  • Data collection focuses on comparative effectiveness and adverse event profiles of the three regimens.
  • The primary outcome measure integrates functional, respiratory, and satisfaction metrics.

Conclusions:

  • Establishing a standard corticosteroid regimen is essential for Duchenne muscular dystrophy care.
  • Optimizing corticosteroid treatment is critical for the efficacy of all emerging add-on therapies for DMD.
  • This trial aims to provide evidence-based guidance for consistent and effective corticosteroid use in DMD management.